Eisai's Lorqess Setback Puts Focus Squarely on Eribulin
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai's recently acquired weight loss drug Lorqess appears set for failure in the hands of U.S. FDA, and while approval rejection would have a small direct impact on the company, the pending approval of eribulin becomes even more vital to a company trying to offset upcoming years of patent losses